SCHEMBL6041694

SCHEMBL6041694

COC(=O)c1ccc2ccc(OCOCC[Si](C)(C)C)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
RAB9A P51151 1/20 0.44
HGFAC Q04756 1/20 0.44
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
PTPN11 Q06124 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CYP19A1 P11511 1/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
LCK P06239 1/20 0.39
CYSLTR1 Q9Y271 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28480511 0.87 MAPT (0.63) MAPTRAB9AKDM4EALDH1A1LMNA
SCHEMBL6041863 0.85 TDP1 (0.49) MAPTALDH1A1TDP1L3MBTL1
SCHEMBL7082367 0.84 PPARG (0.42) RAB9AHTTKDM4EALDH1A1LMNA
SCHEMBL6044419 0.84 CYSLTR1 (0.49) MAPTRAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL5356041 0.83 MAPT (0.54) MAPTRAB9AHGFACALOX15HTT
SCHEMBL15779853 0.82 MAPT (0.50) MAPTRAB9AHGFACALOX15HTT
SCHEMBL14299760 0.79 MAPT (0.53) MAPTRAB9AHGFACALOX15HTT
SCHEMBL3879952 0.78 MAPT (0.71) MAPTRAB9AHGFACALOX15HTT
SCHEMBL6042807 0.78 ALOX15 (0.44) MAPTRAB9AALOX15HTTKDM4E
SCHEMBL6041731 0.78 MAPT (0.46) MAPTRAB9AALOX15HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MAPT 43/4885RAB9A 1698/4885HGFAC 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.